Walter A. Henne

TL;DR: The quest for the ideal targeted therapeutic agent was described, which began with a search for ligands that would bind selectively to pathologic cells, displaying no affinity for healthy cells, and held great promise for increasing the potency while reducing toxicity of many cancer therapies.

TL;DR: Folic acid has been linked to folic acid for tumor-selective drug delivery to avoid the collateral damage that accompanies their uptake by healthy cells as discussed by the authors, which has led to the development of a variety of folate-conjugated drugs for the diagnosis and therapy of cancers and inflammatory/autoimmune diseases.

TL;DR: A folate receptor targeted camptothecin prodrug was synthesized using a hydrophilic peptide spacer linked to folate via a releasable disulfide carbonate linker, demonstrating receptor-mediated uptake.

TL;DR: It is demonstrated that the PSMA-specific ligand, 2-[3-(1, 3-dicarboxy propyl)ureido] pentanedioic acid, is capable of mediating the targeted killing of LNCaP cells with many different therapeutic warheads, suggesting that flexibility can be designed into ligand-targeted therapeutics, enabling adaptation of a single targeting ligand for the treatment of patients with different sensitivities to different chemotherapies.

TL;DR: It is demonstrated that short peptide ligands can be used to efficiently capture Bacillus subtilis spores in liquids and will serve as a platform for the detection of pathogenic organisms including biowarfare agents.